D
Day One Biopharmaceuticals
Cancer drug development comes of age. Follow
About Day One Biopharmaceuticals
Day One Biopharmaceuticals focuses on developing innovative treatments for pediatric cancer through a collaborative approach involving multiple stakeholders. The company operates in the biopharmaceutical industry, targeting unmet medical needs in pediatric oncology. Its business model revolves around drug development, clinical trials, and partnerships with healthcare providers and research institutions. Revenue is generated through the commercialization of successful drug candidates and strategic alliances. Day One Biopharmaceuticals serves patients, healthcare providers, and research communities, aiming to improve outcomes for children with cancer.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Listing
- IPO 2021
- Employees
- 252
- Open positions
- 2
- Dealroom signal
- 88.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Nov 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Day One Biopharmaceuticals.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2026 | $2.5B | $2.5B | Servier | ↗ |
| PRIVATE PLACEMENT VCOther financing | Jul 2024 | $175M | — | Wellington Management · Deerfield · Fairmount Funds Management · Frazier Life Sciences | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $158M | 0% | −$142M | -90% |
| 2025 | $158M | +20.6% | −$142M | -90% |
| 2024 | $131M | — | −$235M | -179.1% |
| 2023 | $0 | — | −$223M | — |
| 2022 | $0 | — | −$147M | — |
| 2021 | $0 | — | −$73M | — |
| 2020 | $0 | — | −$14M | — |
Growth signals
Latest recorded traffic for Day One Biopharmaceuticals is 6.9K monthly website visits, down 46.9% over the last three months. Day One Biopharmaceuticals's team grew 14.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Atlas Venture
Access Biotechnology
Canaan
RA Capital Management
BVF Partners
Viking Global Investors
Perceptive Advisors
Boxer Capital
Franklin Templeton Investments
Janus Henderson Investors
T. Rowe Price
Other known investors6 additional known investors
Deerfield
Servier
Braidwell
Fairmount Funds Management
Frazier Life Sciences
Wellington Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Day One Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Day One Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.